ZYME Zymeworks Inc.
QT60| Index | — | P/E | — | EPS (ttm) | -1.37 | Insider Own | 49.97% | Shs Outstand | 71.90M | Perf Week | 4.44% |
| Market Cap | 2.17B | Forward P/E | 22.75 | EPS next Y | 1.32 | Insider Trans | -0.04% | Shs Float | 68.42M | Perf Month | 14.96% |
| Enterprise Value | 2.16B | PEG | — | EPS next Q | 2.27 | Short Float | 8.15% | Perf Quarter | 28.21% | ||
| Income | -81.00M | P/S | 20.44 | EPS this Y | — | Short Ratio | 7.11 | Perf Half Y | 12.93% | ||
| Sales | 106.00M | P/B | 27.08 | EPS next Y | 11.43% | ROA | -37.78% | Short Interest | 5.58M | Perf YTD | 14.43% |
| Book/sh | 1.11 | P/C | 7.99 | EPS next 5Y | 18.35% | ROE | -72.07% | 52W High | 31.34 -3.86% | Perf Year | 57.83% |
| Cash/sh | 3.77 | P/FCF | — | EPS past 3/5Y | — | ROIC | -43.66% | 52W Low | 16.00 88.31% | Perf 3Y | 353.08% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | -36.40% 22.14% | Gross Margin | 87.78% | Volatility | 3.38% 3.97% | Perf 5Y | 29.87% |
| Dividend TTM | — | EV/Sales | 20.42 | EPS Y/Y TTM | — | Oper. Margin | -418.99% | ATR (14) | 1.13 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 6.32 | Sales Y/Y TTM | -69.11% | Profit Margin | -404.00% | RSI (14) | 67.96 | Recom | 2.09 |
| Dividend Gr. 3/5Y | — | Current Ratio | 6.32 | EPS Q/Q | — | SMA20 | 10.91% | Beta | 1.28 | Target Price | 43.33 |
| Payout | 0.00% | Debt/Eq | 3.36 | Sales Q/Q | -89.80% | SMA50 | 10.23% | Rel Volume | 2.50 | Prev Close | 28.99 |
| Employees | 231 | LT Debt/Eq | 3.33 | Earnings | Nov 09 | SMA200 | 19.17% | Avg Volume | 1.01M | Price | 30.13 |
| IPO Date | Apr 28, 2017 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -7.89% 1.15% | Net Debt/EBITDA | — | Volume | 2,519,221 | Change | 3.93% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-23-26 | Reiterated | Jefferies | Buy | $50 → $52 |
| Oct-07-26 | Reiterated | Truist Securities | Buy | $32 → $34 |
| Aug-26-26 | Reiterated | Deutsche Bank | Buy | $32 |
| Aug-26-26 | Reiterated | HC Wainwright & Co. | Buy | $51 → $55 |
| Aug-07-26 | Reiterated | Stifel Nicolaus | Buy | $47 → $46 |
| Aug-07-26 | Reiterated | Wells Fargo | Overweight | $37 → $40 |
| Aug-07-26 | Reiterated | Truist Securities | Buy | $31 → $32 |
| Aug-05-26 | Reiterated | HC Wainwright & Co. | Buy | $46 → $51 |
| Jul-07-26 | Reiterated | Truist Securities | Buy | $28 → $31 |
| Jun-30-26 | Reiterated | Wells Fargo | Overweight | $33 → $37 |
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 106 | 76 | 76 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 143 | — | — | — | — | — | — | |
| Gross Profit | 106 | 76 | -67 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 62 | 62 | 70 | — | — | — | — | — | — | |
| Research and Development | 137 | 135 | 144 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 16 | -143 | — | — | — | — | — | — | |
| Operating Income | -93 | -137 | -138 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 13 | 20 | 19 | — | — | — | — | — | — | |
| Net Income Before Taxes | -80 | -117 | -119 | — | — | — | — | — | — | |
| Income Taxes | 1 | 6 | -1 | — | — | — | — | — | — | |
| Consolidated Net Income | -81 | -123 | -119 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -81 | -123 | -119 | — | — | — | — | — | — | |
| Net Income | -81 | -123 | -119 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.08 | -1.62 | -1.72 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.08 | -1.62 | -1.72 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.08 | -1.62 | -1.72 | — | — | — | — | — | — | |
| EBITDA | -69 | -109 | -121 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 18.63 | 14.64 | 9.43 | — | — | — | — | — | — | |
| Gross Margin | 100.00 | 100.00 | -88.16 | — | — | — | — | — | — | |
| Operating Margin | -87.74 | -180.26 | -181.58 | — | — | — | — | — | — | |
| Net Margin | -76.42 | -161.84 | -156.58 | — | — | — | — | — | — | |
| Shares Outstanding | 75 | 76 | 69 | — | — | — | — | — | — | |
| Market Capitalization | 1,975 | 1,113 | 717 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Schayowitz Adam | EVP, Head of R&D | Oct 09 '26 | Sale | 25.85 | 13,832 | 357,557 | 23,205 | Oct 09 |
| Schayowitz Adam | EVP, Head of R&D | Oct 09 '26 | Option Exercise | 0.00 | 37,037 | 0 | 37,037 | Oct 09 |
| Hollywood Mark | EVP & Chief Operating Officer | Jan 12 '26 | Option Exercise | 0.00 | 17,666 | 0 | 139,033 | Jan 13 |
| Hollywood Mark | EVP & Chief Operating Officer | Jan 12 '26 | Sale | 22.67 | 6,120 | 138,762 | 132,913 | Jan 13 |
| Smith Jeffrey T L | EVP & Chief Medical Officer | Jan 12 '26 | Option Exercise | 0.00 | 17,666 | 0 | 36,018 | Jan 12 |
| Smith Jeffrey T L | EVP & Chief Medical Officer | Jan 12 '26 | Sale | 22.67 | 9,310 | 211,090 | 26,708 | Jan 12 |
| Moore Paul Andrew | Chief Scientific Officer | Jan 12 '26 | Option Exercise | 0.00 | 17,666 | 0 | 58,057 | Jan 12 |
| Moore Paul Andrew | Chief Scientific Officer | Jan 12 '26 | Sale | 22.67 | 9,560 | 216,759 | 48,497 | Jan 12 |
| Galbraith Kenneth | Chair & CEO | Jan 12 '26 | Option Exercise | 0.00 | 64,000 | 0 | 257,266 | Jan 12 |
| Galbraith Kenneth | Chair & CEO | Jan 12 '26 | Sale | 22.67 | 30,424 | 689,819 | 226,842 | Jan 12 |
| Smith Jeffrey T L | EVP & Chief Medical Officer | Jan 05 '26 | Option Exercise | 0.00 | 20,000 | 0 | 28,890 | Jan 05 |
| Smith Jeffrey T L | EVP & Chief Medical Officer | Jan 05 '26 | Sale | 25.10 | 10,538 | 264,471 | 18,352 | Jan 05 |
| Galbraith Kenneth | Chair & CEO | Jan 05 '26 | Option Exercise | 0.00 | 114,334 | 0 | 224,952 | Jan 05 |
| Galbraith Kenneth | Chair & CEO | Jan 05 '26 | Sale | 25.10 | 54,343 | 1,363,840 | 158,286 | Jan 05 |
| Moore Paul Andrew | Chief Scientific Officer | Jan 05 '26 | Option Exercise | 0.00 | 37,168 | 0 | 51,212 | Jan 05 |